Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ohara Obtains Exclusive Rights to Biliary Tract Cancer Drug
Ohara Pharmaceutical said on April 25 that it has entered into a license and joint development agreement with drug discovery biotech J-Pharma for its biliary tract cancer treatment JPH203. The agreement gives Ohara exclusive rights to research, develop, market, and…
To read the full story
Related Article
- J-Pharma Goes Public on TSE, Eyes Licensing of LAT1 Inhibitors
March 26, 2026
- J-Pharma’s Biliary Tract Cancer Med Hits Mark in Japan PII Study
January 24, 2023
- Ohara Licenses Novel Glioma Treatment from US Pharma Aiming to Bolster Pediatric Pipelines
February 18, 2019
- Generic Player Ohara Looks to Morph into Innovative Drug Maker, with Focus on Oncology
February 13, 2019
- J-Pharma Initiates PI Trial of LAT1 Inhibitor
February 23, 2015
BUSINESS
- Moderna Ratchets Up Oncology Drive with Cancer Vaccine PIII Win
September 15, 2026
- Taiho Takes Small-Molecule Expertise into ADCs; 3-Payload IND Due This Year
September 14, 2026
- Cuorips Raises 4 Billion Yen to Fund Post-Riheart Pipeline
September 14, 2026
- Boehringer, Medical Society Launch ILD Research Grant Program
September 14, 2026
- Otsuka Steps Up Neuroplastogen Push in Psychiatry
September 14, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…